Novocure Announces FDA Approval of IDE Supplement for Phase III Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Novocure, Inc. announced the US FDA has approved the company’s Investigational Device Exemption supplement, reducing the enrollment requirement for its LUNAR trial to 276 patients with 12 months follow-up. LUNAR is a phase 3 pivotal trial testing the effectiveness of Tumor Treating Fields in combination with immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone for patients with stage IV NSCLC who progressed during or after platinum-based therapy.